Shibani Nicum
Overview
Explore the profile of Shibani Nicum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Shakankery K, Kefas J, Palmer K, Houston A, Mukherjee U, Gao K, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518031
Background: Ethnic and socioeconomic disparities in cancer outcomes are exacerbated by clinical trial underrepresentation. This study aims to identify inequalities in ethnicity and socioeconomic features among ovarian cancer clinical trial...
2.
Taylor A, Clement K, Hillard T, Sassarini J, Ratnavelu N, Baker-Rand H, et al.
Post Reprod Health
. 2024 Oct;
30(4):256-279.
PMID: 39394654
These guidelines have been developed jointly by the British Gynaecological Cancer Society and British Menopause Society to provide information for all healthcare professionals managing women treated for gynaecological cancer. Menopausal...
3.
Steventon L, Man K, Nicum S, Miller R, Peleg Hasson S, Shah S, et al.
Oncologist
. 2024 Sep;
29(11):e1532-e1539.
PMID: 39245440
Introduction: Chemotherapy forms the cornerstone of systemic treatment for advanced ovarian cancer, extending overall survival; however, drug-related toxicity can lead to treatment delays, potentially diminishing treatment efficacy. This study evaluated...
4.
Merry E, Kesmez R, Yu T, Flynn M, Ledermann J, Lockley M, et al.
Int J Gynecol Cancer
. 2024 Sep;
PMID: 39231541
Objective: Underrepresentation of elderly ovarian cancer patients in clinical trials has led to lack of clarity regarding optimal first-line chemotherapy in this cohort. The Elderly Women with Ovarian Cancer (EWOC)-1...
5.
Leung E, Nicum S, Morrison J, Brenton J, Funingana I, Morgan R, et al.
Int J Gynecol Cancer
. 2024 Sep;
34(9):1334-1343.
PMID: 39222974
Standard of care genetic testing has undergone significant changes in recent years. The British Gynecological Cancer Society and the British Association of Gynecological Pathologists (BGCS/BAGP) has re-assembled a multidisciplinary expert...
6.
Steventon L, Kipps E, Man K, Roylance R, Forster M, Wong I, et al.
Eur J Cancer
. 2024 Aug;
210:114301.
PMID: 39216173
Background: Inter-cycle delays to chemotherapy are often required to manage drug toxicity. The impact of delays on mortality is poorly characterised. This retrospective cohort study examined the association of treatment...
7.
OMalley D, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, et al.
Future Oncol
. 2024 Jul;
20(32):2423-2436.
PMID: 39082675
At first recurrence, platinum-sensitive ovarian cancer (PSOC) is frequently treated with platinum-based chemotherapy doublets plus bevacizumab, then single-agent bevacizumab. Most patients' disease progresses within a year after chemotherapy, emphasizing the...
8.
Olawaiye A, Kim J, Bagameri A, Bishop E, Chudecka-Glaz A, Devaux A, et al.
J Gynecol Oncol
. 2024 Jul;
35(4):e111.
PMID: 39032926
Background: Ovarian cancer has the highest mortality among gynecologic cancers, primarily because it typically is diagnosed at a late stage and because of the development of chemoresistance in recurrent disease....
9.
Moss E, Taylor A, Andreou A, Ang C, Arora R, Attygalle A, et al.
Eur J Obstet Gynecol Reprod Biol
. 2024 Jul;
300:69-123.
PMID: 39002401
No abstract available.
10.
Michael A, Wilson W, Sunshine S, Annels N, Harrop R, Blount D, et al.
Int J Gynecol Cancer
. 2024 May;
34(8):1225-1231.
PMID: 38760075
Background: Immunotherapy directed at 5T4 tumor antigen may delay the need for further chemotherapy. An attenuated modified vaccinia Ankara virus containing the gene encoding for 5T4 (MVA-5T4) was studied in...